Scarica l'app Stockscreener
5.70
0.19%
0.0106
Dopo l'orario di chiusura:
5.66
-0.04
-0.70%
Intensity Therapeutics Inc Borsa (INTS) Ultime notizie
INTS Stock Price, Quote & Chart | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), IQVIA Holdings (IQV) and Xenon (XENE) - The Globe and Mail
Hedge Fund Bets: What are Intensity Therapeutics Incs recent SEC filings showingMarket Activity Recap & Community Driven Trade Alerts - baoquankhu1.vn
Risk Analysis: What is Intensity Therapeutics Incs debt to equity ratio2026 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Intensity Therapeutics (INTS) CEO receives 37,749-share stock bonus grant - Stock Titan
U.S. Tariff and Trade Policy Risks Threaten Intensity Therapeutics’ Supply Chain, Costs, and Stock Valuation - The Globe and Mail
Short Squeeze: Is Intensity Therapeutics Inc stock a top performer YTD2026 Momentum & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Intensity Therapeutics, Inc. 2025 Annual Report: Innovative Intratumoral Cancer Drug Development and Clinical Pipeline Overview - Minichart
INTS: Promising clinical results and strong 2025 capital raise extend cash runway into Q2 2027 - TradingView
Clinical data and cash runway update for Intensity Therapeutics (NASDAQ: INTS) - Stock Titan
[10-K] INTENSITY THERAPEUTICS, INC. Files Annual Report - Stock Titan
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update - ChartMill
INTS: Paused clinical trials and ongoing losses highlight urgent need for new funding - TradingView
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Market Pulse: Can Fury Gold Mines Limited expand its profit marginsEarnings Performance Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Intensity Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
INTS SEC FilingsINTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
US Market Recap: Does Intensity Therapeutics Inc have strong EBITDA margins2026 Sector Moves & Verified Momentum Watchlists - baoquankhu1.vn
Intensity Therapeutics receives new US patent for cancer treatment By Investing.com - Investing.com Australia
Intensity Therapeutics Expands ATM Equity Offering Capacity - The Globe and Mail
Intensity Therapeutics issued new patent in the US - TipRanks
Intensity Therapeutics receives new US patent for cancer treatment - Investing.com
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US - Finviz
Intensity Therapeutics Inc increases ATM offering capacity to $60 million on March 23, 2026SEC filing - marketscreener.com
Intensity Therapeutics IncIncreases ATM Offering Capacity To $60 Million On March 23, 2026SEC Filing - tradingview.com
Intensity Therapeutics boosts ATM capacity to $60.0M to enhance financing flexibility - TradingView
Intensity Therapeutics (NASDAQ: INTS) boosts $60M at-the-market capacity - Stock Titan
Intensity Therapeutics (NASDAQ: INTS) raises ATM capacity to $60M - Stock Titan
If You Invested $1,000 in INTENSITY THERAPEUTICS INC (INTS) - Stock Titan
Is Intensity Therapeutics Inc currently under institutional pressure2026 Trends & High Win Rate Trade Tips - baoquankhu1.vn
Block Trades: Is Intensity Therapeutics Inc currently under institutional pressureWeekly Market Outlook & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Technical Analysis: Is Intensity Therapeutics Inc stock a top performer YTD2026 Retail Activity & Growth Focused Investment Plans - baoquankhu1.vn
Aug Rallies: Should I set a stop loss on Intensity Therapeutics Inc2026 Rallies & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Forecast Cut: Can Intensity Therapeutics Inc ride the EV waveWeekly Profit Analysis & Technical Entry and Exit Alerts - baoquankhu1.vn
Intensity Therapeutics regains compliance with Nasdaq's minimum bid price requirement - MSN
Intensity Therapeutics reports early trial data in breast cancer - Investing.com Nigeria
Intensity Therapeutics updates breast cancer trial, files to resume enrollment following study pause - MSN
Intensity Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Nigeria
Alliance Global Partners Sticks to Their Buy Rating for Intensity Therapeutics, Inc. (INTS) - The Globe and Mail
Intensity Therapeutics Inc (INTS) Stock Price, Quote, News & History - Benzinga
Intensity Therapeutics price target adjusted to $30 at Alliance Global - TipRanks
Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause - Sahm
Intensity Therapeutics reports early trial data in breast cancer By Investing.com - Investing.com Australia
Intensity Therapeutics provides update on INVINCIBLE-4 Study - TipRanks
Ballard Reports Q4 2025 and Full Year Results - Weekly Voice
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study - ChartMill
Bear Alert: Is Intensity Therapeutics Inc likely to announce a buyback2026 Intraday Action & Growth Focused Investment Plans - baoquankhu1.vn
Take Profit: Should I set a stop loss on Intensity Therapeutics Inc2026 Outlook & Safe Entry Point Identification - baoquankhu1.vn
Intensity Therapeutics Regains Nasdaq Compliance, Stabilizing Market Listing - The Globe and Mail
Investment Review: Can Intensity Therapeutics Inc disrupt its industryQuarterly Earnings Report & Daily Oversold Bounce Ideas - baoquankhu1.vn
What's going on with Intensity Therapeutics stock Friday? - MSN
CT biotech firm regains Nasdaq compliance after carrying out reverse-stock split - Hartford Business Journal
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):